Moderna trains its mRNA tech on the common cold and a triple whammy against 3 respiratory diseases Ex-Biogen R&D chief Al Sandrock lands CEO job at Voyager, taking over the Big Pharma darling in early days of its turnaround strategy After going 0 for 2, AnaptysBio CEO makes immediate exit, leaving a strategic portfolio review in his wake Sponsored: Bridging the preclinical to clinical divide: practical considerations for biomarker success Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field Sponsored: Unlocking the power of AI-driven pathology in drug development: An Interview with Bristol Myers Squibb Aligos hacks off 2nd hep B med since January after 'unexpected' reaction in 4 patients ORIC walks away from lead cancer resistance program after lackluster phase 1b data An mRNA therapy improves breast cancer response to immunotherapy in mice Virtual clinical trials market worth $8B as CROs rush to add decentralized capabilities Merck, building on Keytruda’s landmark biomarker nod, pressures GSK's limited I-O position with new FDA approval MIT, Mass General researchers develop handheld robot for tapping into blood vessels #FierceMadness: Grab a bracket and help us determine healthcare's biggest power broker! As rivals eye 'unjustified royalties,' Pfizer partner sues to defend COVID-19 shot Comirnaty Study: Rural hospital closures over latest decade affected more Black and Hispanic residents Featured Story | By Annalee Armstrong Moderna is adding two more vaccine programs to its roster: a combination respiratory candidate and a shot targeting all four endemic human coronaviruses that cause the common cold. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Al Sandrock, M.D., Ph.D., has identified the destination of his post-Biogen voyage. Months after leaving Biogen in the wake of the Aduhelm debacle, Sandrock has taken up the CEO position at Voyager Therapeutics, putting him in charge of a next-generation gene therapy play that has been attracting Big Pharma interest. read more By Nick Paul Taylor Back-to-back failures have spurred AnaptysBio to take stock. CEO Hamza Suria has left, bringing an end to his 11-year reign, and the board of directors is carrying out a strategic portfolio review of AnaptysBio’s three wholly owned clinical-phase programs. read more Sponsored by: Precision for Medicine To successfully advance preclinical biomarker assays from the bench to the bedside, it is crucial to develop a clear plan for delivering assays that can be used within the clinical trial setting. Learn strategies for assessing and optimizing biomarker feasibility and utility to support study success. read more By Max Bayer Affini-T Therapeutics CEO Jak Knowles, M.D., is no stranger to the kind of startups that draw early capital, having once been vice president of venture investments for Bayer’s VC arm, Leaps by Bayer. But now, he’s the one asking for money, and his former employer is ready to dole it out. read more Sponsored by: PathAI Learn how Bristol Myers Squibb is unlocking new insights in translational research and development by transforming pathology with artificial intelligence read more By Max Bayer Aligos Therapeutics has ended development of its second med since January after four patients fell ill in a phase 1 trial testing its treatment for chronic hepatitis B, including one person who was hospitalized. As a result, the company is pivoting its pipeline to focus on small-molecule therapies. read more By Annalee Armstrong ORIC Pharmaceuticals is walking away from the lead program used to underpin its 2020 IPO after the cancer med did not demonstrate adequate clinical activity in several early-stage trials. read more By Angus Liu A team of scientists in Spain has discovered a promising approach to increasing immunotherapy's effectiveness in triple-negative breast cancer by targeting cancer stem cells. The researchers created a mRNA therapy prototype based on the findings and showed promising results in mice. read more By Annalee Armstrong Clinical trials are going virtual at a rapid clip after the COVID-19 pandemic, and Medi-Tech Insights says the market is now worth nearly $8 billion. read more By Angus Liu Following a historic biomarker-driven FDA approval in 2017, Merck's Keytruda has expanded its label in one cancer subtype with that genetic abnormality, further pressuring GlaxoSmithKline's latecomer Jemperli. read more By Conor Hale The system uses an artificial intelligence-powered ultrasound scanner to guide needles and catheter hardware, to help stem severe bleeding or deliver fluids and medications all while potentially in the back of an ambulance. read more By Paige Minemyer This year, Fierce Healthcare's #FierceMadness is back, and we want you to help us identify the industry's most influential person. read more By Eric Sagonowsky Pfizer has already reeled in tens of billions of dollars in sales for its COVID-19 shot Comirnaty. Now, one of the company's partners says rival companies are eyeing "hundreds of millions, if not billions, of dollars in unjustified royalties" through a potential patent lawsuit. read more By Robert King A new study found rural hospital closures from 2010 to 2020 affected a larger share of Black and Hispanic residents compared with prior decades. read more Resources Sponsored by: H1 Read why many MSLs are still challenged in developing integrated strategies to increase the volume of meaningful engagements. Download this industry report to find out what the top challenges are and suggestion strategies to solve them. Download now. Sponsored by: Medidata, a Dassault Systèmes company The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates. Sponsored by: Thermo Fisher Scientific Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Oracle Health Sciences How to overcome top challenges faced in decentralized trials. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 